Psagot Value Holdings’s AstraZeneca AZN Stock Holding History

Psagot Value Holdings’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-750	Closed	-$106K	–	514
2023 Q2	$106K	Sell	750 -6,050	-89%	-$890K	0.05%	210
2023 Q1	$933K	Buy	+6,800	New	+$915K	0.39%	58

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Psagot Value Holdings's AZN Position: Q3 2023 in Review

Psagot Value Holdings sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 750 shares — an estimated $106K sold.

Psagot Value Holdings first reported a position in AZN in Q1 2023 and held it in 2 quarters. The position peaked at $933K in Q1 2023. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Psagot Value Holdings reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
Psagot Value Holdings sold 750 AstraZeneca shares in Q3 2023, an estimated $106K.
Psagot Value Holdings first reported a position in AstraZeneca in Q1 2023 and held it in 2 quarters.
Psagot Value Holdings's AstraZeneca position peaked at $933K in Q1 2023.
1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Psagot Value Holdings's 13F filing for Q3 2023, filed 30 Oct 2023.